ELI LILLY AND COMPANY Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period
ELI LILLY AND COMPANY (LLY) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period of -745.00 thousand shares for the 12-month period ending 2010-12-31, per its 10-K filed 2011-02-22.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod · last filed 2011-02-22
- ELI LILLY AND COMPANY share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2010 was -745.00K shares.
- ELI LILLY AND COMPANY share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2009 was -559.00K shares.
- ELI LILLY AND COMPANY share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2008 was -301.00K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 12 month |
|---|---|
| 2010-12-31 | -745.00K shares 10-K · filed 2011-02-22 |
| 2009-12-31 | -559.00K shares 10-K · filed 2011-02-22 |
| 2008-12-31 | -301.00K shares 10-K · filed 2011-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |